Novocure (NSDQ:NVCR) said that the 1st patient has been enrolled in a Phase III pivotal trial of its tumor-treating field technology in combination with radiosurgery to treat brain metastases from non-small-cell lung cancer.
The St. Helier, N.J.-based company’s tumor treating fields (TTFields) are low-intensity, intermediate-frequency, alternating electric fields designed to disrupt cell division within cancer cells. Novocure’s commercial product, Optune, is indicated in the U.S. as a therapy in combination with temozolomide to treat gliobastoma.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure enrolls 1st patient in phase III brain metastases trial appeared first on MassDevice.
from MassDevice http://ift.tt/2dkmDNm
Cap comentari:
Publica un comentari a l'entrada